Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [10]

CheckMate067 outcomes: Nivolumab plus ipilimumab in advanced melanoma

Dr Jedd Wolchok - Memorial Sloan Kettering Center, New York, USA

CheckMate067 outcomes: Nivolumab plus ipilimumab in advanced melanoma ( Dr Jedd Wolchok - Memorial Sloan Kettering Center, New York, USA )

Radiation and immunology – a new therapeutic partnership

Dr Ralph Weichselbaum - University of Chicago, Chicago, USA

Radiation and immunology – a new therapeutic partnership ( Dr Ralph Weichselbaum - University of Chicago, Chicago, USA )

Initial nivolumab-based treatment halts melanoma progression

Dr Jedd Wolchok - Memorial Sloan-Kettering Cancer Center, New York, USA

Initial nivolumab-based treatment halts melanoma progression ( Dr Jedd Wolchok - Memorial Sloan-Kettering Cancer Center, New York, USA )

Phase III study finds initial nivolumab-based treatment halts melanoma...

Dr Jedd Wolchok - Memorial Sloan-Kettering Cancer Center, New York, USA

Phase III study finds initial nivolumab-based treatment halts melanoma progression ( Dr Jedd Wolchok - Memorial Sloan-Kettering Cancer Center, New York, USA )

Phase I study measures effect of ipilimumab and nivolumab combination in...

Prof Jedd Wolchok - Memorial Sloan-Kettering Cancer Center, New York, USA

Phase I study measures effect of ipilimumab and nivolumab combination in melanoma patients ( Prof Jedd Wolchok - Memorial Sloan-Kettering Cancer Center, New York, USA )

Nivolumab with peptide vaccine in patients naive to or that failed ipilimumab

Dr Jeffrey Weber - Moffitt Cancer Center, Tampa, USA

Nivolumab with peptide vaccine in patients naive to or that failed ipilimumab ( Dr Jeffrey Weber - Moffitt Cancer Center, Tampa, USA )

Ipilimumab and BRAF inhibitors for advanced melanoma

Dr Lynn Schuchter - University of Pennsylvania, USA

Ipilimumab and BRAF inhibitors for advanced melanoma ( Dr Lynn Schuchter - University of Pennsylvania, USA )

Nivolumab produces long-lasting responses in patients with stage IV melanoma

Dr Mario Sznol - Yale Cancer Center, New Haven, USA

Nivolumab produces long-lasting responses in patients with stage IV melanoma ( Dr Mario Sznol - Yale Cancer Center, New Haven, USA )

Immunotherapy treatment for melanoma

Prof Jedd Wolchok - Memorial Sloan-Kettering Cancer Center, New York, USA

Immunotherapy treatment for melanoma ( Prof Jedd Wolchok - Memorial Sloan-Kettering Cancer Center, New York, USA )

Ipilimumab improves survival in metastatic melanoma

Prof Jedd Wolchok - Memorial Sloan-Kettering Cancer Center, New York, USA

Ipilimumab improves survival in metastatic melanoma ( Prof Jedd Wolchok - Memorial Sloan-Kettering Cancer Center, New York, USA )

More from ecancer